Drug Profile

PD 1 dependent interleukin 2 - Bonum Therapeutics

Alternative Names: PD-1 dependent IL-2

Latest Information Update: 28 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Good Therapeutics
Developer Bonum Therapeutics
Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
Mechanism of Action Interleukin 2 replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Aug 2025 No recent reports of development identified for research development in Cancer in USA (Parenteral)
15 Nov 2022 Good Therapeutics has been acquired by Roche and renamed to Bonum Therapeutics
12 Jul 2021 Early research in Cancer in USA (Parenteral), before July 2021 (Good Therapeutics pipeline, July 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com